MDNews - Mid Penn

Innovations 2017

Issue link: http://viewer.e-digitaledition.com/i/884976

Contents of this Issue

Navigation

Page 8 of 19

THE PENN STATE PL A STIC SURGERY TE AM AT PENN STATE HE ALTH MILTON S. HERSHE Y MEDICAL CENTER IS PERFORMING ADVANCED RESE ARCH THAT IS LE ADING TO THE DE VELOPMENT OF STEM CELLŸDERIVED ߟCELLS WITH THE POTENTIAL TO RE VOLUTIONIZE DIABE TES TRE ATMENT. ROUGHLY 30 MILLION A MERICA NS have diabetes, according to the American Diabetes Association. Treatments may include insulin therapy and medication, in addition to blood glucose monitoring and lifestyle changes. However, even with these treatments, many patients fail to achieve adequate glycemic control. Autologous transplantation of stem cell-derived ß-cells may ser ve a s a n optimal — potentially even curative — therapy for diabetes. Dino Ravnic, DO, MPH, assistant professor of surgery at Milton S. Hershey Medica l Center, is exploring the feasibility and efficacy of using adipose-derived stem cells to create these ß-cells. FROM LABORATORY TO CLINIC Currently, most researchers use embryonic or induced pluripotent stem cells for ß-cell generation, according to Dr. Ravnic. Now, according to a study published in Stem Cells and Development, bone marrow stem cells have also been used to induce development of ß-cells, and the cells created are capable of producing low levels of insulin in culture. The use of adipose-derived stem cells is less established but could o‡er several advantages, not the least of which, adipose- der ived stem cel ls eliminate et hica l concerns a ssociated w ith embr yonic stem cells, as well as the potentia l for teratomas, which may occur following transplantation of induced pluripotent stem cells. In addition, most patients have excess adipose tissue; adipose tissue o‡ers a richer source of stem cells per gram than bone marrow — 5,000 versus 100– 1,000, according to the Stem Cells and Development study. Successf u l prelim ina r y st udies in which Dr. Ravnic isolated adipose-derived stem cells and performed a monthlong di‡erentiation protocol resulted in the development of insulin-producing ß-cells. Within the next six months, Dr. Ravnic hopes to set up animal studies to further evaluate the cells. While it is too early to draw definitive conclusions, he believes this therapy may serve as a maintenance treatment for type 1 diabetes. If further investigation reveals it is feasible and e‡ective, insulin- dependent patients may be able to replace multiple daily insulin injections with one or more injections of stem cell-derived ß-cel ls delivered over t he course of their lifetimes. "Using adipose-derived stem cells to develop insulin-producing beta cells has the potential to benefit a large portion of the population," Dr. Ravnic says. "We are still within the basic-science realm and have only just scratched the surface of this technique. Much more thorough investigation is required going into the future, which, of course, we are prepared to do." ■ " Research can be costly and time-prohibitive, but it is the only way to advance medicine. The availability of this technique is representative of the large number of Penn State Health clinicians and researchers who have innovative ideas that are expanded on with vigorous support from the health system." DINO RAVNIC, DO, MPH, ASSISTANT PROFESSOR OF SURGERY AT MILTON S. HERSHEY MEDICAL CENTER Stem Cell-derived ß-cells Hold Promise of Advancing Diabetes Care BY TIFFANY PARNELL M D N E W S .C O M /// M D N E W S M I D P E N N ■ 2 017 R E S E A R C H 0 9

Articles in this issue

Archives of this issue

view archives of MDNews - Mid Penn - Innovations 2017